Table 4 Subgroup analysis on risk of herpes zoster on rheumatoid arthritis patients during first bDMARD or tsDMARD use

Sex

0.783

 Men

1.79 (0.95–3.37)

1.72 (0.85–3.47)

2.13 (1.14–3.99)*

1.52 (0.72–3.25)

1.16 (0.56–2.41)

1.26 (0.16–9.90)

2.51 (0.81–7.83)

Reference

 Women

1.09 (0.84–1.41)

1.26 (0.97–1.66)

1.15 (0.89–1.48)

0.97 (0.71–1.33)

0.84 (0.62–1.13)

1.17 (0.56–2.44)

2.41 (1.52–3.81)***

Reference

Age, years

0.163

 ≥65

1.39 (0.90–2.16)

1.21 (0.74–1.99)

1.43 (0.91–2.24)

1.12 (0.65–1.94)

1.06 (0.65–1.73)

0.48 (0.06–3.64)

3.82 (1.92–7.59)***

Reference

 <65

1.13 (0.85–1.51)

1.36 (1.01–1.83)*

1.21 (0.92–1.59)

1.00 (0.71–1.42)

0.79 (0.57–1.10)

1.35 (0.64–2.84)

1.93 (1.12–3.34)*

Reference

No. of csDMARD

0.993

 ≤2

1.23 (0.90–1.68)

1.38 (0.98–1.94)

1.34 (0.98–1.83)

1.24 (0.85–1.79)

0.93 (0.65–1.32)

1.48 (0.66–3.30)

2.45 (1.44–4.17)**

Reference

 >2

1.13 (0.79–1.63)

1.34 (0.92–1.95)

1.23 (0.86–1.75)

0.83 (0.52–1.34)

0.82 (0.53–1.29)

0.84 (0.20–3.49)

2.39 (1.16–4.94)*

Reference

CCI

0.649

 ≤2

0.77 (0.51–1.16)

1.00 (0.65–1.53)

0.90 (0.60–1.35)

0.77 (0.47–1.26)

0.64 (0.39–1.04)

0.73 (0.22–2.42)

1.52 (0.65–3.54)

Reference

 >2

1.43 (1.07–1.91)*

1.48 (1.08–2.03)*

1.46 (1.10–1.96)*

1.17 (0.82–1.67)

0.99 (0.71–1.38)

1.48 (0.63–3.45)

2.86 (1.75–4.69)***

Reference

Steroids^a

0.132

 ≥5 mg/day

1.20 (0.85–1.68)

1.52 (1.05–2.20)*

1.43 (1.02–1.99)*

1.07 (0.69–1.65)

1.01 (0.68–1.51)

2.50 (1.05–5.95)*

1.92 (1.03–3.59)*

Reference

 <5 mg/day

1.18 (0.84–1.64)

1.22 (0.87–1.73)

1.16 (0.83–1.62)

1.03 (0.70–1.53)

0.78 (0.53–1.14)

0.57 (0.18–1.86)

3.24 (1.80–5.83)***

Reference